EP Patent

EP1915129A2 — Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation

Assigned to Chiesi Farmaceutici SpA · Expires 2008-04-30 · 18y expired

What this patent protects

The invention relates to a liquid, propellant-free pharmaceutical formulation in the form of ready-to-use preparation for administration by nebulisatioη comprising a water soluble salt of the beta2-agonist 8-hydroxy-5- [1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]…

USPTO Abstract

The invention relates to a liquid, propellant-free pharmaceutical formulation in the form of ready-to-use preparation for administration by nebulisatioη comprising a water soluble salt of the beta2-agonist 8-hydroxy-5- [1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2( 1H)- quinolinone as active ingredient. The active ingredient is chemically stable in the formulation, and said formulation is provided of an adequate shelf-life suitable for commercial distribution, storage and use.

Drugs covered by this patent

Patent Metadata

Patent number
EP1915129A2
Jurisdiction
EP
Classification
—
Expires
2008-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Chiesi Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.